These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

224 related items for PubMed ID: 3928305

  • 1. [Suppression of platelet aggregation as a result of two-component inhibition of a polyenzyme system of thromboxane synthesis].
    Varfolomeev SD, Lakin KM, Mevkh AT, Novikova NV, Rukazenkov IuZ.
    Dokl Akad Nauk SSSR; 1985; 282(1):194-6. PubMed ID: 3928305
    [No Abstract] [Full Text] [Related]

  • 2. Influence of selective thromboxane synthetase blocker CGS-13080 on thromboxane and prostacyclin biosynthesis in whole blood: evidence for synthesis of prostacyclin by leukocytes from platelet-derived endoperoxides.
    Mehta J, Mehta P, Lawson DL, Ostrowski N, Brigmon L.
    J Lab Clin Med; 1985 Sep; 106(3):246-52. PubMed ID: 3928780
    [Abstract] [Full Text] [Related]

  • 3. Inhibition of arachidonate metabolism by selected compounds in vitro with particular emphasis on the thromboxane A2 synthase pathway.
    Tobias LD, Hamilton JG.
    Adv Prostaglandin Thromboxane Res; 1980 Sep; 6():453-6. PubMed ID: 6770605
    [No Abstract] [Full Text] [Related]

  • 4. Studies of the influence of nitroglycerin on the synthesis of prostaglandins and thromboxane A2 and on platelet aggregation.
    Rettkowski W, Pönicke K, Block HU, Giessler C, Dunemann A, Zehl U, Förster W.
    Arzneimittelforschung; 1982 Sep; 32(3):194-200. PubMed ID: 6805480
    [Abstract] [Full Text] [Related]

  • 5. Evidence that prostaglandin endoperoxides can induce platelet aggregation in the absence of thromboxane A2 production.
    Hornby EJ, Skidmore IF.
    Biochem Pharmacol; 1982 Mar 15; 31(6):1158-60. PubMed ID: 7200773
    [No Abstract] [Full Text] [Related]

  • 6. Pharmacology of thromboxane synthetase inhibitors.
    Smith JB.
    Fed Proc; 1987 Jan 15; 46(1):139-43. PubMed ID: 3542573
    [Abstract] [Full Text] [Related]

  • 7. Endogenous prostacyclin contributes to the efficacy of a thromboxane synthetase inhibitor for preventing coronary artery thrombosis.
    Aiken JW, Shebuski RJ, Miller OV, Gorman RR.
    J Pharmacol Exp Ther; 1981 Nov 15; 219(2):299-308. PubMed ID: 6270303
    [No Abstract] [Full Text] [Related]

  • 8. Biochemical and pharmacological evaluation of thromboxane synthetase inhibitors.
    Gorman RR.
    Adv Prostaglandin Thromboxane Res; 1980 Nov 15; 6():417-25. PubMed ID: 6247892
    [No Abstract] [Full Text] [Related]

  • 9. [Synthesis of thromboxane A2: limiting stages of primary thrombocyte aggregation in humans initiated by arachidonic acid and its metabolic products].
    Mevkh AT, Basevich VV, Varfolomeev SD.
    Biokhimiia; 1984 Dec 15; 49(12):2035-40. PubMed ID: 6441604
    [Abstract] [Full Text] [Related]

  • 10. Inhibition of platelet aggregation by 1-alkylimidazole derivatives, thromboxane A synthetase inhibitors.
    Kayama N, Sakaguchi K, Kaneko S, Kubota T, Fukuzawa T, Kawamura S, Yoshimoto T, Yamamoto S.
    Prostaglandins; 1981 Apr 15; 21(4):543-54. PubMed ID: 7196056
    [Abstract] [Full Text] [Related]

  • 11. A comparative study of the involvement of the prostaglandin H2/thromboxane A2 pathway in intravascular platelet aggregation in guinea-pigs and rats.
    Mallarkey G, Smith GM.
    Br J Pharmacol; 1985 Feb 15; 84(2):425-30. PubMed ID: 3156648
    [Abstract] [Full Text] [Related]

  • 12. [Pharmacological action on the thromboxane and prostacyclin balance in the body].
    Lakin KM, Makarov VA, Novikova NV, Tret'iak VM, Rukazenkov IuE.
    Farmakol Toksikol; 1984 Feb 15; 47(2):67-79. PubMed ID: 6425078
    [No Abstract] [Full Text] [Related]

  • 13. Modulation of human platelet function by prostacyclin and thromboxane A2.
    Gorman RR.
    Fed Proc; 1979 Jan 15; 38(1):83-8. PubMed ID: 215465
    [No Abstract] [Full Text] [Related]

  • 14. A comparative evaluation of thromboxane receptor blockade, thromboxane synthase inhibition and both in animal models of arterial thrombosis.
    Salvati P, Dho L, Ukmar G, Vaga L, Rimoldi O, Patrono C.
    J Pharmacol Exp Ther; 1994 Apr 15; 269(1):238-45. PubMed ID: 8169831
    [Abstract] [Full Text] [Related]

  • 15. Potentiation by dazoxiben, a thromboxane synthetase inhibitor, of platelet aggregation inhibitory activity of a thromboxane receptor antagonist and of prostacyclin.
    Bertele V, De Gaetano G.
    Eur J Pharmacol; 1982 Dec 03; 85(3-4):331-3. PubMed ID: 6295787
    [Abstract] [Full Text] [Related]

  • 16. Selective blockade of thromboxane A2 synthesis during experimental E coli bacteremia in the goat. Effects on hemodynamics and lung water.
    Harlan J, Winn R, Weaver J, Hildebrandt J, Harker L.
    Chest; 1983 May 03; 83(5 Suppl):75S-76S. PubMed ID: 6340988
    [No Abstract] [Full Text] [Related]

  • 17. Platelet rich plasma transforms exogenous prostaglandin endoperoxide H2 into thromboxane A2.
    Fitzpatrick FA, Gorman RR.
    Prostaglandins; 1977 Nov 03; 14(5):881-9. PubMed ID: 594390
    [Abstract] [Full Text] [Related]

  • 18. Pharmacologic inhibition of thromboxane synthetase and platelet aggregation: modulatory role of cyclooxygenase products.
    Bertelé V, Falanga A, Tomasiak M, Chiabrando C, Cerletti C, de Gaetano G.
    Blood; 1984 Jun 03; 63(6):1460-6. PubMed ID: 6426554
    [Abstract] [Full Text] [Related]

  • 19. The biochemical pharmacology of thromboxane synthase inhibition in man.
    FitzGerald GA, Reilly IA, Pedersen AK.
    Circulation; 1985 Dec 03; 72(6):1194-201. PubMed ID: 3905048
    [Abstract] [Full Text] [Related]

  • 20. Pharmacology and endogenous roles of prostaglandin endoperoxides, thromboxane A2, and prostacyclin.
    Moncada S, Vane JR.
    Pharmacol Rev; 1978 Sep 03; 30(3):293-331. PubMed ID: 116251
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.